Pulmonary embolism treatment

Pulmonary embolism represents one of the most urgent conditions in pulmonary and cardiovascular medicine, caused by obstruction of pulmonary arteries that interrupts blood flow and impairs oxygen exchange. It frequently arises from deep vein thrombosis in the legs, though other risk factors include surgery, prolonged immobility, cancer, and inherited clotting disorders. Clinical signs may be subtle, such as unexplained shortness of breath or chest pain, but in severe cases patients can deteriorate rapidly with shock or cardiac arrest. Rapid recognition and confirmation through diagnostic imaging, particularly CT pulmonary angiography, have greatly improved outcomes in recent years.

Modern pulmonary embolism treatment now emphasizes a risk-based approach rather than uniform protocols. Anticoagulation therapy remains the foundation, with direct oral anticoagulants gaining preference for their predictable effects and minimal monitoring requirements. For unstable patients with massive emboli, systemic thrombolysis, catheter-based clot removal, or surgical embolectomy are life-saving interventions. In intermediate-risk patients, decisions must carefully weigh the potential benefits of aggressive intervention against bleeding risks. Beyond the acute phase, clinicians focus on long-term strategies—deciding optimal anticoagulation duration, monitoring for recurrence, and preventing chronic complications such as thromboembolic pulmonary hypertension.

Equally important are supportive measures: encouraging mobility, managing comorbidities, and educating patients about lifestyle changes and adherence to therapy. The rise of dedicated pulmonary embolism response teams highlights the value of multidisciplinary care, ensuring coordinated, timely treatment. With advances in pharmacology, interventional techniques, and personalized risk assessment, pulmonary embolism treatment continues to evolve toward safer, more effective, and patient-centered outcomes.